Business Description
Eloxx Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US29014R1032
Description
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.83 | |||||
| Equity-to-Asset | -3.32 | |||||
| Debt-to-Equity | -0.29 | |||||
| Debt-to-EBITDA | -0.32 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 32.9 | |||||
| 3-Year EPS without NRI Growth Rate | 32.4 | |||||
| 3-Year FCF Growth Rate | 29.1 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.41 | |||||
| 9-Day RSI | 52.16 | |||||
| 14-Day RSI | 49.53 | |||||
| 6-1 Month Momentum % | -33.77 | |||||
| 12-1 Month Momentum % | -86.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.24 | |||||
| Quick Ratio | 0.24 | |||||
| Cash Ratio | 0.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -29.4 | |||||
| Shareholder Yield % | 219.34 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -152.31 | |||||
| ROIC % | -113.56 | |||||
| ROC (Joel Greenblatt) % | -2355.33 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.2 | |||||
| EV-to-Forward-EBIT | -0.29 | |||||
| EV-to-EBITDA | -0.21 | |||||
| EV-to-Forward-Revenue | 5.07 | |||||
| EV-to-FCF | -0.2 | |||||
| Earnings Yield (Greenblatt) % | -500 | |||||
| FCF Yield % | -629.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ELOX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eloxx Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -9.07 | ||
| Beta | 2.72 | ||
| Volatility % | 233.91 | ||
| 14-Day RSI | 49.53 | ||
| 14-Day ATR ($) | 0.073187 | ||
| 20-Day SMA ($) | 0.942961 | ||
| 12-1 Month Momentum % | -86.49 | ||
| 52-Week Range ($) | 0.4 - 10.9 | ||
| Shares Outstanding (Mil) | 3.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eloxx Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eloxx Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eloxx Pharmaceuticals Inc Frequently Asked Questions
What is Eloxx Pharmaceuticals Inc(ELOX)'s stock price today?
The current price of ELOX is $0.91. The 52 week high of ELOX is $10.90 and 52 week low is $0.40.
When is next earnings date of Eloxx Pharmaceuticals Inc(ELOX)?
The next earnings date of Eloxx Pharmaceuticals Inc(ELOX) is 2024-05-15 Est..
Does Eloxx Pharmaceuticals Inc(ELOX) pay dividends? If so, how much?
Eloxx Pharmaceuticals Inc(ELOX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers